FSD Pharma

FSD Pharma, Inc. is a specialty biotech pharmaceutical research and development company. It focuses on developing over time a robust pipeline of FDA-approved synthetic compounds targeting the end cannabinoid system of the human body to treat certain diseases of the central nervous system and autoimmune disorders of the skin, GI tract, and the musculoskeletal system. The company was founded by Thomas Fairfull, Zeeshan Saeed and Anthony J. Durkacz on October 20, 1994 and is headquartered in Toronto, Canada.

Earnings data Q3 2020

Earnings data Q4 2020

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Quantum Biopharma Ltd. is a biotechnology pharmaceutical research and development company, which focuses on the cultivation, process, and sale of medical cannabis. It operates through the Biotechnology and Strategic Investments segments. The Biotechnology segment is involved in the research and development of the company's three drug candidates consisting of FSD-PEA, Lucid-PSYCH, and Lucid-MS. The Strategic Investments segment is focused on generating returns and cashflow through the issuance of loans secured by residential or commercial property. The company was founded by Thomas Fairfull, Zeeshan Saeed and Anthony J. Durkacz on October 20, 1994 and is headquartered in Toronto, Canada.

FSD Pharma Inc (CSE:HUGE, NASDAQ:HUGE) said recruiting is underway for the Phase 2 clinical trial of FSD-PEA (FSD201) for the treatment of chronic pain associated with idiopathic Mast Cell Activation Syndrome (MCAS) at two clinical sites in the US while a Canadian site is to be ready to recruit soon. The Toronto-based biopharmaceutical company said FSD201 is a proprietary anti-inflammatory compound with the potential to address a wide range of inflammatory diseases and associated conditions.

FSD Pharma says recruiting underway in Phase 2 Trial of FSD201 for treating chronic pain associated with idiopathic MCAS

TORONTO--( BUSINESS WIRE )--FSD Pharma Inc. (NASDAQ: HUGE) (CSE: HUGE) (FRA: 0K9A) (“FSD Pharma” or the “Company”), a biopharmaceutical company dedicated to building a portfolio of innovative assets and biotech solutions to address ailments affecting millions worldwide, today announces recruiting is underway for the Company's Phase 2 clinical trial of FSD201 for the treatment of chronic pain associated with idiopathic MCAS (MCAD) at two clinical sites in the USA, and a Canadian site to be ready to recruit soon. The trial and its status are available on ClinicalTrials.gov (Identifier: NCT05652907).

Recruiting Underway in FSD Pharma's Phase 2 Trial of FSD-PEA (FSD201) for the Treatment of Chronic Pain Associated With Idiopathic MCAS (MCAD)

FSD Pharma Inc (CSE:HUGE, NASDAQ:HUGE) announced it has submitted a Clinical Trial Application (CTA) for a planned Phase-1 clinical trial for Lucid-MS, a candidate for the treatment of multiple sclerosis (MS). In a statement, FSD Pharma called Lucid-MS a “first-in-class neuroprotective compound” with a novel mechanism action that has shown to prevent myelin degradation, which can cause MS and other neurodegenerative diseases.

FSD Pharma submits clinical trial application for its multiple sclerosis treatment candidate Lucid-MS

TORONTO--( BUSINESS WIRE )--FSD Pharma Inc. (NASDAQ: HUGE) (CSE: HUGE) (FRA: 0K9A) (“FSD Pharma” or the “Company”), a biopharmaceutical company dedicated to building a portfolio of innovative assets and biotech solutions to address ailments affecting millions worldwide, today announces the submission of the Company's Clinical Trial Application (CTA) for a planned Phase-1 clinical trial for Lucid-MS, a candidate for the treatment of Multiple Sclerosis (MS).

FSD Pharma submits its phase-1 Clinical Trial Application for Lucid-MS (Lucid-21-302) for first-in-human safety and tolerability investigation

FSD Pharma Inc (CSE:HUGE, NASDAQ:HUGE) said its board of directors has approved a share repurchase program that will allow the company to buy back up to 1.9 million of its subordinate Class B voting shares over the next 12 months.  “FSD Pharma is focused on the advancement of its drug candidates toward the clinic, and we recognize there may be a strategic opportunity to enhance shareholder value without compromising our ambitious growth plans,” the company's interim CEO Anthony Durkacz said in a statement.

FSD Pharma plans buyback of up to 1.9 million shares to utilize cash reserves

TORONTO--( BUSINESS WIRE )--FSD Pharma Inc. (NASDAQ: HUGE) (CSE: HUGE) (FRA: 0K9A) (“FSD Pharma” or the “Company”), a biopharmaceutical company dedicated to building a portfolio of innovative assets and biotech solutions to address ailments affecting millions worldwide, is pleased to announce that its Board of Directors has authorized the repurchase under a normal course issuer bid (“NCIB”) of up to 1,925,210 of its Subordinate Class B Voting Shares (the “Subordinate Voting Shares”) from time to time over the next 12 months at prevailing market prices in order to allow the Company to use its excess cash reserves to strategically return value to shareholders.

FSD Pharma Announces Share Repurchase Program

FSD Pharma Inc (CSE:HUGE, NASDAQ:HUGE) has announced the incorporation of a new subsidiary to capitalize on drug development incentives in Australia. The Toronto-based biopharma firm told investors it has also appointed a number of new doctors to its Scientific and Clinical Expert Committee and is investigating other products addressing acute medical needs due to substances of abuse such as alcohol.

FSD Pharma incorporates new subsidiary to capitalize on drug development incentives in Australia

TORONTO--( BUSINESS WIRE )--FSD Pharma Inc. (NASDAQ: HUGE) (CSE: HUGE) (FRA: 0K9A) (“FSD Pharma” or the “Company”), a biopharmaceutical company dedicated to building a portfolio of innovative assets and biotech solutions to address ailments affecting millions worldwide, is pleased to announce:

FSD Pharma Inc Incorporates New Subsidiary to Capitalize on Drug Development Incentives in Australia

TORONTO--( BUSINESS WIRE )--FSD Pharma Inc. (NASDAQ: HUGE) (CSE: HUGE) (FRA: 0K9A) (“FSD Pharma” or the “Company”), a biopharmaceutical company dedicated to building a portfolio of innovative assets and biotech solutions to address ailments affecting millions worldwide, announced today that senior executive management is attending the 41st Annual J.P. Morgan Healthcare Conference being held January 9-12, 2023, in San Francisco, California. The J.P. Morgan Healthcare Conference is the largest and most informative healthcare investment symposium in the industry, connecting global industry leaders, emerging fast-growth companies, innovative technology creators and members of the investment community.

FSD Pharma to Attend 41st Annual J.P. Morgan Healthcare Conference 2023

FSD Pharma Inc (CSE:HUGE, NASDAQ:HUGE) has announced the appointments of Dr Lakshmi P. Kotra and Joseph L.

FSD Pharma announces changes to its board of directors

TORONTO--( BUSINESS WIRE )--FSD Pharma Inc. (NASDAQ: HUGE) (CSE: HUGE) (FRA: 0K9A) (“FSD Pharma” or the “Company”), a biopharmaceutical company dedicated to building a portfolio of innovative assets and biotech solutions to address ailments affecting millions worldwide, is pleased to announce the appointments of Dr. Lakshmi P. Kotra and Mr. Joseph L. Romano to its Board of Directors, effective November 25, 2022. Effective at the same time was the resignation of Fernando Cugliari from the Board of Directors.

FSD Pharma Announces Changes to the Board of Directors

TORONTO--(BUSINESS WIRE)---- $HUGE #FSDPharma--FSD Pharma Inc. (NASDAQ: HUGE) (CSE: HUGE) (FRA: 0K9) (“FSD Pharma” or the “Company”), a biopharmaceutical company dedicated to building a portfolio of innovative assets and biotech solutions to address ailments affecting millions worldwide, today announced that the claim for USD $30.2 million brought by the Company's former CEO, Dr. Raza Bokhari, was dismissed yesterday, November 9, 2022.

FSD Pharma Announces Arbitrator Dismisses Claims by Former CEO, Dr. Raza Bokhari

TORONTO--(BUSINESS WIRE)---- $HUGE #FSDPharma--FSD Pharma Inc. (NASDAQ: HUGE) (CSE: HUGE) (FRE: 0K9A) (“FSD Pharma” or the “Company”), a biopharmaceutical company dedicated to building a portfolio of innovative assets and biotech solutions to address ailments affecting millions worldwide, today announces that it is presenting and participating via the on-demand session at the H.C. Wainwright 24th Annual Global Investment Conference taking place September 12-14, 2022. FSD Pharma's on-demand presentation can be acces

FSD Pharma Participating in H.C. Wainwright 24th Annual Global Investment Conference, On-Demand Presentation Available

FSD Pharma Inc (CSE:HUGE, NASDAQ:HUGE) revealed that it has received a study may proceed letter for its Investigational New Drug (IND) application from the US Food and Drug Administration (FDA) and notice of authorization from Health Canada for its Phase 2 clinical trial of FSD201.   The Toronto-based biopharma firm said the corresponding study protocol is titled "A Randomized, Double-Blind Placebo Controlled Parallel Group Study of Safety and Efficacy of FSD201 in Patients with Chronic Widespread Musculoskeletal Nociplastic Pain Associated with Idiopathic Mast Cell Activation Syndrome.

FSD Pharma wins FDA and Health Canada approval for IND for Phase 2 Trial of FSD201 for treating inflammatory disorder

TORONTO--(BUSINESS WIRE)---- $HUGE #FSDPharma--FSD Pharma Inc. (NASDAQ: HUGE) (CSE: HUGE) (FRE: 0K9A) (“FSD Pharma” or the “Company”), a biopharmaceutical company dedicated to building a portfolio of innovative assets and biotech solutions to address ailments affecting millions worldwide, today announces that it received “Study May Proceed” letter for the Investigational New Drug (“IND”) application from the U.S. Food and Drug Administration (“FDA”) and “Notice of Authorization” from Health Canada for its Phase 2 c

FDA and Health Canada Clear IND for FSD Pharma to Proceed with Phase 2 Trial of FSD201 for Nociplastic Pain Associated with Idiopathic Mast Cell Activation Syndrome

FSD Pharma (CSE:HUGE, NASDAQ:HUGE) Inc announced that its wholly-owned Lucid Psycheceuticals Inc subsidiary has filed a provisional patent application on novel formulations of palmitoylethanolamide (PEA). The Toronto-based biotechnology company said the new patent application is based on the results of completed preclinical animal toxicology studies and phase 1 clinical trial using FSD201 (ultramicronized PEA), sponsored by FSD Pharma (CSE:HUGE, NASDAQ:HUGE).

FSD Pharma says Lucid Psycheceuticals subsidiary files patent for novel PEA formulations; presents preclinical toxicology results at international symposium

TORONTO--(BUSINESS WIRE)---- $HUGE #FSDPharma--FSD Pharma Inc. (NASDAQ: HUGE) (CSE: HUGE) (FRE: 0K9A) (“FSD Pharma” or the “Company”), a life sciences holding company dedicated to building a portfolio of assets and biotech solutions, announced today that is wholly owned subsidiary, Lucid Psycheceuticals Inc. (“Lucid”), filed a provisional patent application on novel formulations of palmitoylethanolamide (PEA). The new patent application is based on the results of completed preclinical animal toxicology studies and

FSD Pharma Subsidiary Lucid Psycheceuticals Files for Patent On Novel Formulations of Palmitoylethanolamide, Presents Preclinical Toxicology Results at an International Symposium

TORONTO--(BUSINESS WIRE)---- $HUGE #FSDPharma--FSD Pharma Inc. (NASDAQ: HUGE) (CSE: HUGE) (FRE: 0K9A) (“FSD Pharma” or the “Company”), a life sciences holding company dedicated to building a portfolio of assets and biotech solutions, announced today the results of its annual general meeting of shareholders (“AGM”), held online and in virtual-only format on June 23, 2022. There were 164 shareholders represented in person or by proxy at the AGM holding 48 Class A Multiple Voting Shares (“Class A Shares”) and 7,885,95

FSD Pharma Inc. Announces Results of Annual General Meeting of Shareholders And Other Corporate Updates

FSD Pharma (CSE:HUGE, NASDAQ:HUGE) Inc has announced that it has submitted Investigation New Drug applications to the US Food and Drug Administration (FDA) and Health Canada for its planned Phase 2 clinical trial of FSD-201 for the treatment of a yet-to-be-disclosed inflammatory disorder. The biotech noted that FSD-201, its proprietary formulation of ultra micronized palmitoylethanolamide, or ultramicronized PEA, was shown to be safe and well tolerated during a Phase 1 clinical trial.

FSD Pharma submits IND applications to the FDA and Health Canada for Phase 2 clinical trial of FSD-201 to treat an inflammatory disorder

TORONTO--(BUSINESS WIRE)---- $HUGE #FSDPharma--FSD Pharma Inc. (NASDAQ: HUGE) (CSE: HUGE) (FRE: 0K9A) (“FSD Pharma” or the “Company”), a life sciences holding company dedicated to building a portfolio of assets and biotech solutions, today announces the submission of an Investigational New Drug (“IND”) application with the U.S. Food and Drug Administration (“FDA”) and Health Canada detailing a planned Phase 2 clinical trial of FSD-PEA for the treatment of a yet-to-be-disclosed inflammatory disorder. “Our current su

FSD Pharma Files Investigational New Drug Application (“IND”) with FDA and Health Canada for Phase-2 Trial of FSD-201 for an Inflammatory disorder and Provides Corporate Updates

TORONTO--(BUSINESS WIRE)--FSD Pharma Inc. (NASDAQ: HUGE) (CSE: HUGE) (FRE: 0K9A) (“FSD Pharma” or the “Company”), a life sciences holding company dedicated to building a portfolio of assets and biotech solutions, announced today that it has issued a management information circular in respect of the annual general meeting of shareholders to be held on June 23, 2022 (the “Circular”). The Circular is available on the Company's profile on SEDAR at www.sedar.com. Additionally, to provide added flexi

FSD Pharma Issues Circular, Adopts Incentive Plan and Grants PSUs

FSD Pharma (CSE:HUGE, NASDAQ:HUGE) Inc announced that it has closed the sale of its former cannabis processing facility in Cobourg, Ontario, Canada for gross proceeds of $16.4 million in cash.  The facility became non-essential to FSD Pharma after it decided in early 2020 to exit the cannabis production market to focus on the biotech market, advancing novel drug candidates targeting lucrative areas of unmet medical needs like Muscular Sclerosis, Depression Disorders, and Inflammatory Disorders.

FSD Pharma closes $16.4M sale of former cannabis processing plant

TORONTO--(BUSINESS WIRE)---- $HUGE #FSDPharma--FSD Pharma Inc. (NASDAQ: HUGE) (CSE: HUGE) (FRE: 0K9A) (“FSD Pharma” or the “Company”), a life sciences holding company dedicated to building a portfolio of assets and biotech solutions, is pleased to announce today the closing of the sale of the Company's former cannabis processing facility located in Cobourg, Ontario, Canada (the “Facility”) for gross proceeds of CAD$16,400,000 in cash. The sale, completed on May 6, 2022, included a 26.1-hectacre parcel of land and 5

FSD Pharma Closes CAD$16.4 Million Sale of Non-Core Assets

TORONTO--(BUSINESS WIRE)---- $HUGE #FSDPharma--FSD Pharma Inc. (NASDAQ: HUGE) (CSE: HUGE) (FRA: 0K9) (“FSD Pharma” or the “Company”), a life sciences holding company dedicated to building a portfolio of assets and biotech solutions, announced today that the Company was successful in its motion to dismiss the derivative claim that was filed by Mr. Maheep Goyal, a shareholder (the “Plaintiff”) on July 20, 2021 in Delaware against the Company and its directors and officers (the “Claim”). In a decision dated May 5, 202

FSD Pharma Announces Dismissal of Derivative Complaint

TORONTO--(BUSINESS WIRE)--FSD Pharma Inc. (NASDAQ: HUGE) (CSE: HUGE) (FRE: 0K9A) (“FSD Pharma” or the “Company”), a life sciences holding company dedicated to building a portfolio of assets and biotech solutions, announced today that on April 15th, 2022, the Company entered into a contract with Tekkfund Capital Corp (“TCC”) for services to structure and assist with certain business development strategies (the “TCC Agreement”), pursuant to which the Company will (i) pay TCC a monthly fee of C$12

News for FSD Pharma Stock (HUGE)